A recent study by Coll et al. (72) showed that the pharmacological blockade of canonical and non-canonical NLRP3 activation with MCC950, a recognized selective, small molecule inhibitor of NLRP3, reduced IL-1β tissue levels and attenuated the severity of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (72). The gene discussed is IL1B; the disease is multiple sclerosis.